Articles related to CARDIOVASCULAR EVENTS

Despite having anti-psychotic, anxiolytic, sedative, and hypnotic properties, quetiapine is linked to an increased risk of cardiovascular death and sudden cardiac death when used in conventional doses. For the first time, the current investigation demonstrated that quetiapine taken off-label and in modest doses raises the risk of major adverse cardiovascular events (MACE), stroke, and cardiovascular death.

Exploring the Korean National Health Insurance claims database revealed that rhythm control via ablation or drugs, initiated within 1 year of diagnosis of AF, was associated with lower risk for cardiovascular events. This held true for both low risk and higher risk patients. The study analyzed data on more than 35,000 patients with a median age of 70.

In a prospective study following the diet and activity records of more than 100,000 individuals in France, artificial sweeteners were positively correlated with cardiovascular diseases. Analyzing 900,000 person-years of data showed: Total artificial sweetener intake was associated with CVD risk Artificial sweeteners were more strongly associated with cerebrovascular disease Aspartame was associated with increase cerebrovascular events Acesulfame K and sucralose were associated with increased coronary heart disease risk

To assess short-term risk for severe cardiovascular events (excluding myocarditis and pericarditis) after COVID-19 vaccination, adults younger than 75 years hospitalized for PE, acute MI, hemorrhagic stroke, or ischemic stroke (73,325 events) were reviewed in relation to a 1st or 2nd COVID vaccine dose. No association was found between the Pfizer–BioNTech or Moderna vaccine and severe cardiovascular events. The first dose of the Oxford–AstraZeneca vaccine was associated with acute MI and PE in the second week after vaccination. An association with MI in the second week after a single dose of the Janssen vaccine could not be ruled out.

The USPSTF comes to the conclusion that statin use has at least a moderate net benefit for adults aged 40 to 75 who have no prior history of CVD, at least one CVD risk factor, and an estimated 10-year CVD event risk of 10% or greater. There is at least a marginal net benefit from using statins to prevent CVD events and all-cause mortality in adults aged 40 to 75 who have no prior history of CVD, at least one of these risk factors, and an estimated 10-year CVD event risk of 7.5% to less than 10%. Still, is the evidence enough?

This review with case example explores pericarditis and myocarditis and implications on limiting exercise. The authors summarize relevant guidelines and provide their own conclusion and guidance. They offer a helpful algorithm combining the ESC, ACC, and AHA guidelines and suggest an additional element around limiting heart rate during an acute inflammatory episode.